Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Quince Therapeutics, Inc. (QNCX:NASDAQ), powered by AI.
Quince Therapeutics, Inc. is currently trading at $0.12. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Quince Therapeutics, Inc. on Alpha Lenz.
Quince Therapeutics, Inc.'s P/E ratio is -0.1.
“Quince Therapeutics, Inc. trades at a P/E of -0.1 (undervalued) with modest ROE of -98.6%.”
Ask for details →Quince Therapeutics Inc. is a biotechnology company focused on discovering and developing innovative therapies aimed at treating medical conditions with a significant unmet need. By leveraging advanced technologies, the company dedicates its resources towards creating novel therapeutics that address the underlying mechanisms of diseases. Quince Therapeutics operates within the pharmaceutical and biotechnology sector, impacting both the healthcare and life sciences industries. The company's research and development initiatives are crucial in the realm of rare diseases and complex medical disorders, where few effective treatments are currently available. Through strategic partnerships and collaborations, Quince Therapeutics endeavours to translate scientific breakthroughs into practical, patient-centric solutions. In the broader financial market, Quince Therapeutics plays an integral role in driving innovation and progress within the healthcare sector, contributing to advancements that can lead to better patient outcomes and quality of life improvements worldwide. As a biotechnology entity, Quince Therapeutics is integral in the ongoing efforts to bring cutting-edge therapies from concept to clinical reality.
“Quince Therapeutics, Inc. trades at a P/E of -0.1 (undervalued) with modest ROE of -98.6%.”
Ask for details →Quince Therapeutics, Inc. (ticker: QNCX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 36 employees. Market cap is $5M.
The current price is $0.124 with a P/E ratio of -0.09x and P/B of 0.18x.
ROE is -98.63%.